Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Pricing of Public Offering of Common Stock

MORRIS PLAINS, N.J., June 13, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...
June 11, 2018 16:13 ET | Source: Immunomedics, Inc.

Immunomedics Announces Proposed Public Offering of Common Stock

MORRIS PLAINS, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...
June 04, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics Provides Business Update at the ASCO 2018 Investor Event

CHICAGO, June 04, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC),...
June 03, 2018 20:00 ET | Source: Immunomedics, Inc.

Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers

Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca® (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial...
June 03, 2018 10:15 ET | Source: Immunomedics, Inc.

Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer

Confirmed Overall Response Rate of 31 Percent; with Median Duration of Response of 7.4 Months and Median Progression-free Survival of 6.8 Months CHICAGO, June 03, 2018 (GLOBE NEWSWIRE) --...
June 01, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer

MORRIS PLAINS, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...
May 30, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Jefferies 2018 Global Healthcare Conference

MORRIS PLAINS, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed...
May 21, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration

MORRIS PLAINS, N.J., May 21, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed...
May 16, 2018 17:01 ET | Source: Immunomedics, Inc.

Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer

Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile Full Data will be Reported in Oral Presentation at 2018...
May 09, 2018 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update

Biologics License Application (BLA) Remains on Track to be Submitted by the End of May 2018 Leadership Team Expanded with Appointment of Dr. Robert Iannone, Head of Research & Development and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right